Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10532966 | 0.93 | ACMSD (0.53) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL28096306 | 0.92 | HSP90AA1 (0.55) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL10534783 | 0.92 | HSP90AA1 (0.55) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL4574951 | 0.90 | MAPK1 (0.49) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL11163887 | 0.86 | CYP2C9 (0.49) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL11163840 | 0.86 | CYP2C9 (0.49) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL19899529 | 0.86 | GPR35 (0.55) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL27038239 | 0.85 | MAPK1 (0.50) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL9375032 | 0.82 | CYP2C9 (0.40) | MAPK1GPR35ALDH1A1TP53HPGD | |
| SCHEMBL9375042 | 0.82 | CYP2C9 (0.40) | MAPK1GPR35ALDH1A1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | disclosed |
| CN-109923111-A | ANTIBIOTIC COMPOUNDS | 迪斯库瓦有限公司 | 2019-06-21 | — | — | CN | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| CN-1147482-C | Substittued (dihydro)benzoxazole and (dihydro)benzoxazine compound and their preparation and medicine composite | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
| US-6620809-B2 | Useful in treating or in preventing melatoninergic disorders | LES LABORATOIRES SERVIER (FR) | 2003-09-16 | — | — | US | disclosed |
| EP-1106608-B1 | Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-03-05 | — | — | EP | disclosed |
| CN-1308069-A | Substittued (dihydro)benzoxazole and (dihydro)benzoxazine compound and their preparation and medicine composite | ADIR (FR) | 2001-08-15 | — | — | CN | disclosed |
| US-20010003747-A1 | New substituted (dihydro)benzoxazine and (dihydro)benzothiazine compounds | LES LABORATOIRES SERVIER (FR) | 2001-06-14 | — | — | US | disclosed |
| EP-1106608-A1 | Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003747-A1 | New substituted (dihydro)benzoxazine and (dihydro)benzothiazine compounds | MTNR1A, MTNR1B, SQOR | MAPK1 2118/4885GPR35 249/4885ALDH1A1 79/4885 |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | MAPK1 1898/4885GPR35 1158/4885ALDH1A1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.